AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment

1. Enhertu's Breakthrough: Enhertu, a HER2-directed antibody-drug conjugate (ADC), has demonstrated a median progression-free survival of 13.2 months in patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy.
2. ASCO Presentation: The results of the DESTINY-Breast06 Phase III trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting Enhertu's potential to become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.
3. Improved Outcomes: Enhertu showed a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HER2-low and HER2-ultralow metastatic breast cancer.
4. Global Collaboration: AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize Enhertu, with Daiichi Sankyo responsible for manufacturing and supply.
5. Comprehensive Portfolio: AstraZeneca has a comprehensive portfolio of approved and promising compounds in development to address the biologically diverse breast cancer tumor environment.
6. Potential in Multiple Settings: Enhertu is being explored in various settings, including HER2-positive and HER2-low metastatic breast cancer, and in combination with other anti-cancer treatments such as immunotherapy.
7. FDA Approvals: Enhertu has received multiple FDA approvals, including for HER2-positive and HER2-low breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and recently, for tumor-agnostic use in HER2-positive solid tumors.